We hope to build on our expertise supporting kidney transplant patients. Our ongoing programme of collaboration and outreach with the nephrology community allows us to continue research in this area.
Astellas’ commitment to nephrology
At Astellas, Changing tomorrow is the ethos that guides everything we do. We work to turn innovative science into value for patients. Our research is focused predominantly in areas of high unmet need in under-served, serious diseases, and our work in nephrology is living proof of this.
We have dedicated more than 20 years to the transplantation community, including those with kidney disease, and are continuing to innovate for kidney transplant patients. Now, our support of patients with kidney disease uncovers new needs, and our expertise in nephrology means we are ideally positioned to address them.
Nephrology is a therapy area focused on the kidneys, specifically kidney function and kidney disease, the preservation of kidney health and the treatment of kidney disease, from diet and medication to renal replacement therapy.
About chronic kidney disease (CKD)
CKD is defined as the progressive loss of kidney function over time.1 It occurs when a disease or condition impairs kidney function, causing kidney damage to worsen over several months or years. Diabetes and high blood pressure are responsible for up to two-thirds of all cases of CKD.1
In Europe one in eight people are living with CKD,2 and it is predicted to become the fifth most common cause of premature death globally by 2040.3,4
About anaemia of CKD
Based on data from the UK, one in five people with CKD develop anaemia.5 Anaemia occurs when the production of red blood cells is reduced, impairing the delivery of oxygen to tissues and organs.6 People with anaemia of CKD can experience a similar reduction in quality of life to those with diabetes, epilepsy and certain forms of cancer.7
Hear from Simi and Paul as they discuss how anaemia of CKD has impacted their lives.
Hear from key expert Dr Sunil Bhandari, consultant in general medicine and nephrology, about the burden of anaemia of CKD and the challenges of its management.
1 National Kidney Foundation. About chronic kidney disease. Available from: https://www.kidney.org/atoz/content/about-chronic-kidney-disease [Last accessed: July 2020].
2 International Society of Nephrology. Chronic kidney disease. Global kidney health atlas [online] 2019. Available from: www.theisn.org/global-atlas [Last accessed: July 2020].
3 Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018;392:2052–2090.
4 Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME, 2018. Available from: http://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf [Last accessed: April 2020].
5 Dmitrieva O, de Lusignan S, Macdougall IC, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol 2013;14:24.
6 Eckardt KU. Anaemia in end-stage renal disease: pathophysiological considerations. Nephrol Dial Transplant 2001;16(Suppl 7):2–8.
7 Eriksson D, Goldsmith D, Teitsson S, et al. Cross-section survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol 2016;17:97.
NEPH_2020_0164_APE. August 2020